Table 1 Relationship between prechemotherapy absolute serum CA125 levels and survival in ovarian cancer
From: Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
First Author, Year, Study Place | Data Collection | Study Design | Sample Size | Groups being Compared | RR/HR, (95% CI), P-Value | Conclusion | Variables Adjusted for |
|---|---|---|---|---|---|---|---|
Markman M, 2006, USA, [37] | NA | Longitudinal study | 101 | ≤ 35 U/ml, > 35-- < 100 U/ml, ≥ 100 U/ml | NA | Reduction in serum CA-125 concentration over the initial 2 cycles of chemotherapy was an independent predictor of survival | NA |
Riedinger JM, 2006, France [38] | 1988 to 1996 | Multicentric retrospective study | 631 | ≤ 230 kU/L & > 230 kU/L | Univariate analysis 0.77 (0.73--0.81), < 0.0001 | Pre-chemotherapy CA125 had a univariate prognostic value for disease free survival and overall survival | NA |
Gronlund B, 2005, Denmark [39] | Dec 1993 to Sep 1998 | Prospective study | 70 | Multiple cutoffs of 35, 65, 132 & 339 U/mL | NA | The pretreatment CA125 level was not found to be significantly associated with survival by any of the cutoffs | FIGO stage, histology, localization of tumor relapse, size of tumor relapse, CASA level |
Gadducci A, 1995, Italy [40] | 1986 to 1992 | Multicentric retrospective study | 225 | < 500 U/ml, ≥ 500 U/ml | NA | Survival was found to be significantly related to serum CA 125 before the third cycle | FIGO stage, tumor grade, residual disease, CA125 half life |
Ron IG, 1994, Israel [41] | Feb 1987 to Dec 1990 | Prospective study | 48 | 35-100 U/ml, 101-299 U/ml, 300-499 U/ml, ≥ 500 U/ml | NA, < 0.0001 | Early response (CA125 normalcy by the end of the second chemotherapeutic course) was a highly significant predictor of disease-free survival at 12 months | Age, FIGO stage, histology, grade, residual tumor, ascites |
Davidson NG, 1991, [42] | Sep 1985 to Sep 1987 | Convenience sample | 55 | < 50 kU/l, 125 ≥ 50 kU/l | NA, < 0.003 | Prechemotherapy CA125 level taken 4 weeks after debulking surgery may predict survival in ovarian cancer patients who undergo chemotherapy treatment | Age, Histology, FIGO stage, tumor grade, residual disease |
Rustin GJ, 1989, U.K. [43] | April 1985 to Feb 1987 | Prospective study | 54 | ≥ 35 U/ml, < 35 U/ml | NA, 0.001 | There was a highly significant relationship between the progression free survival time and the change in CA125 levels just prior to chemotherapy | NA |
van der Burg ME, 1988, Netherland [44] | Sept 1979 to Dec 1983 | Consecutive case series | 85 | ≤ 35 U/ml, 35-60 U/ml, > 60 U/ml | NA | The prechemotherapy level of CA125 on itself is strongly correlated with progression rate and the probability of progression within 3 years | FIGO stage, histology, histological grade, postoperative tumor size |